menu
    • menu
    [{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rovatirelin","moa":"Thyrotropin releasing hormone receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Kissei Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"CG0070","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Affamed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series D Financing","leadProduct":"CG0070","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravesical Injection","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carotegrast Methyl","moa":"Alpha4 integrin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Immunology","graph2":"Approved","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CG0070","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Kissei Pharmaceutical \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ CG Oncology"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Kissei Pharmaceutical","amount2":0.16,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Kissei Pharmaceutical \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Kissei Pharmaceutical \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Kissei Pharmaceutical

    Menu

    Kissei Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Tai Tien Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma Signs Fostamatinib Sub-Licensing Agreement with Kissei

                            Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Tai Tien Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rigel Expands REZLIDHIA® Partnership with Kissei for Japan, Korea, Taiwan

                            Details : The agreement aims to develop and commercialize Rezlidhia (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan.

                            Product Name : Rezlidhia

                            Product Type : Small molecule

                            Upfront Cash : $10.0 million

                            September 03, 2024

                            Lead Product(s) : Olutasidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

                            Details : The Phase 3 clinical study (n=34) showed that patients receiving Tavalisse(Fostamatinib Disodium Hexahydrate) achieved a stable platelet response significantly higher than patients receiving a placebo control for the treatment of adult chronic immune thr...

                            Product Name : Tavalisse

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2021

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Sanwa Kagaku Kenkyusho

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patien...

                            Details : UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.

                            Product Name : Upasita

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2021

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Sanwa Kagaku Kenkyusho

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG0070

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CG Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Participation in Global Phase III Clinical Trial For CG0070, a Drug for Bladder Cancer

                            Details : CG0070, a oncolytic immunotherapy in which adenovirus is genetically modified to enhance bladder tumor cells selectivity and anticancer activity, and is injected into the bladder using a urinary tract catheter.

                            Product Name : CG0070

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 24, 2021

                            Lead Product(s) : CG0070

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CG Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Rituximab,Cyclophosphamide

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Amgen Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kissei Pharmaceutical Reports Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Recep...

                            Details : If approved, avacopan would be the first-in-class orally administered selective complement 5a receptor inhibitor exerting an anti-inflammatory effect, for the treatment of patients with ANCA-associated vasculitis.

                            Product Name : CCX168

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2021

                            Lead Product(s) : Avacopan,Rituximab,Cyclophosphamide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Amgen Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotegrast Methyl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : EA Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Results of Phase III Clinical Study of AJM300 for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/C...

                            Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.

                            Product Name : AJM300

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 13, 2021

                            Lead Product(s) : Carotegrast Methyl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : EA Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG0070

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : CG Oncology

                            Deal Size : $47.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            CG Oncology Closes $47 Million Series D Financing

                            Details : The financing will support the advancement of CG Oncology’s late-stage clinical programs for its lead oncolytic immunotherapy, CG0070, including an ongoing global Phase 3 trial (BOND3) with CG0070 and a combination Phase 2 study of CG0070 with KEYTRUDA...

                            Product Name : CG0070

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 10, 2020

                            Lead Product(s) : CG0070

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : CG Oncology

                            Deal Size : $47.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KDT-3594

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Affamed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease

                            Details : Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.

                            Product Name : KDT-3594

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 09, 2020

                            Lead Product(s) : KDT-3594

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Affamed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG0070,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : CG Oncology

                            Deal Size : $140.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical

                            Details : The licensing agreement will provide production and commercial prospects for the immunotherapy drug CG0070 from CG Oncology in Japan, South Korea, Taiwan and other Asian countries, except China.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : $10.0 million

                            March 26, 2020

                            Lead Product(s) : CG0070,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : CG Oncology

                            Deal Size : $140.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth